Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 391 to 405 of 438 results for cardiovascular disease

  1. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

  2. Air pollution: outdoor air quality and health (NG70)

    This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.

  3. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

  4. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  5. Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)

    Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).

  6. What is the most clinically and cost-effective tool for diagnosing peripheral arterial disease in people with diabetes?

    arterial disease in people with diabetes? Any explanatory notes(if applicable) People with diabetes are at higher risk of...

  7. Off-pump coronary artery bypass grafting (IPG377)

    Evidence-based recommendations on off-pump coronary artery bypass grafting. This involves attaching a healthy blood vessel to the heart muscle so that blood can get round (‘bypass’) the affected part of the coronary artery.

  8. Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG649)

    Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults. This involves attaching a clip to the leaflets of the mitral valve.

  9. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  10. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.

  11. Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (IPG380)

    Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.

  12. Preparing for the next breakthroughs in liver disease treatments

    With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.

  13. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

  14. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.